Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6553693 | 0.86 | F10 (0.55) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6553711 | 0.86 | F10 (0.44) | F10F2SLC2A1PKM | |
| SCHEMBL6553729 | 0.79 | CDK1 (0.38) | F10F2ALDH1A1POLBCDK1 | |
| Trifluoroacetic Acid SCHEMBL6857468 | 0.79 | F10 (0.51) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL6553831 | 0.70 | F10 (0.38) | F10F2PKM | |
| SCHEMBL3896153 | 0.70 | F2 (0.46) | F10F2EPHX2CDK1NAMPT | |
| Trifluoroacetic Acid SCHEMBL6553710 | 0.69 | F10 (0.61) | F10F2EPHX2 | |
| Trifluoroacetic Acid SCHEMBL7568684 | 0.69 | F10 (0.80) | F10F2 | |
| SCHEMBL3899503 | 0.67 | NPC1 (0.53) | ALDH1A1POLBCDK1 | |
| Trifluoroacetic Acid SCHEMBL6857491 | 0.66 | F10 (0.36) | F10F2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784191-B2 | AS BLOOD-COAGULATION INHIBITOR OR AN AGENT FOR THERAPY AND PROPHYLAXIS OF THROMBOSIS OR EMBOLISM, CONTAINING | AJINOMOTO CO., INC. (JP) | 2004-08-31 | — | — | US | disclosed |
| EP-1236735-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-20020193348-A1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1236735-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193348-A1 | Benzamidine derivatives | SERPINC1, SERPINE1, TFPI | F10 14/4885F2 4/4885ALDH1A1 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.